Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients

A. Gringeri; E. Santagostino; M. Muça-Perja; P. M. Mannucci; J. F. Zagury; B. Bizzini; A. Lachgar; M. Carcagno; J. Rappaport; M. Criscuolo; W. Blattner; A. Burny; R. C. Gallo; D. Zagury

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients

A. Gringeri, E. Santagostino, M. Muça-Perja, P. M. Mannucci, J. F. Zagury, B. Bizzini, A. Lachgar, M. Carcagno, J. Rappaport, M. Criscuolo, W. Blattner, A. Burny, R. C. Gallo, D. Zagury

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Objectives: To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HFV-1 vaccine using an inactivated but immunogenic Tat (Tat toxoid). Tat toxoid has been assayed for safety and immunogenicity in seropositive patients. Method: The phase I vaccine clinical trial testing Tat toxoid preparation in Seppic Isa 51 oil adjuvant was performed on 14 HIV-1-infected asymptomatic although biologically immunocompromized individuals (500-200 CD4⁺ cells/mm³). Results: Following as many as 8 injections, no clinical defects were observed. All patients exhibited an antibody (Ab) response to Tat, and some had cell-mediated immunity (CMI) as evaluated by skin test in vivo and T-cell proliferation in vitro. Conclusion: These results provide initial evidence of safety and potency of Tat toxoid vaccination in HIV-1-infected individuals.

Original language	English
Pages (from-to)	293-298
Number of pages	6
Journal	Journal of Human Virology
Volume	1
Issue number	4
Publication status	Published - May 1998

Keywords

AIDS
Immunization
Immunotherapy
Tat protein

ASJC Scopus subject areas

Virology

Fingerprint Dive into the research topics of 'Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients'. Together they form a unique fingerprint.

Cite this

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. / Gringeri, A.; Santagostino, E.; Muça-Perja, M.; Mannucci, P. M.; Zagury, J. F.; Bizzini, B.; Lachgar, A.; Carcagno, M.; Rappaport, J.; Criscuolo, M.; Blattner, W.; Burny, A.; Gallo, R. C.; Zagury, D.

In: Journal of Human Virology, Vol. 1, No. 4, 05.1998, p. 293-298.

Research output: Contribution to journal › Article › peer-review

Gringeri, A. ; Santagostino, E. ; Muça-Perja, M. ; Mannucci, P. M. ; Zagury, J. F. ; Bizzini, B. ; Lachgar, A. ; Carcagno, M. ; Rappaport, J. ; Criscuolo, M. ; Blattner, W. ; Burny, A. ; Gallo, R. C. ; Zagury, D. / Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. In: Journal of Human Virology. 1998 ; Vol. 1, No. 4. pp. 293-298.

@article{a7446661e99c431884a8bbe0ae8ddf82,

title = "Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients",

abstract = "Objectives: To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HFV-1 vaccine using an inactivated but immunogenic Tat (Tat toxoid). Tat toxoid has been assayed for safety and immunogenicity in seropositive patients. Method: The phase I vaccine clinical trial testing Tat toxoid preparation in Seppic Isa 51 oil adjuvant was performed on 14 HIV-1-infected asymptomatic although biologically immunocompromized individuals (500-200 CD4+ cells/mm3). Results: Following as many as 8 injections, no clinical defects were observed. All patients exhibited an antibody (Ab) response to Tat, and some had cell-mediated immunity (CMI) as evaluated by skin test in vivo and T-cell proliferation in vitro. Conclusion: These results provide initial evidence of safety and potency of Tat toxoid vaccination in HIV-1-infected individuals.",

keywords = "AIDS, Immunization, Immunotherapy, Tat protein",

author = "A. Gringeri and E. Santagostino and M. Mu{\c c}a-Perja and Mannucci, {P. M.} and Zagury, {J. F.} and B. Bizzini and A. Lachgar and M. Carcagno and J. Rappaport and M. Criscuolo and W. Blattner and A. Burny and Gallo, {R. C.} and D. Zagury",

year = "1998",

month = may,

language = "English",

volume = "1",

pages = "293--298",

journal = "Journal of Human Virology",

issn = "1090-9508",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients

AU - Gringeri, A.

AU - Santagostino, E.

AU - Muça-Perja, M.

AU - Mannucci, P. M.

AU - Zagury, J. F.

AU - Bizzini, B.

AU - Lachgar, A.

AU - Carcagno, M.

AU - Rappaport, J.

AU - Criscuolo, M.

AU - Blattner, W.

AU - Burny, A.

AU - Gallo, R. C.

AU - Zagury, D.

PY - 1998/5

Y1 - 1998/5

N2 - Objectives: To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HFV-1 vaccine using an inactivated but immunogenic Tat (Tat toxoid). Tat toxoid has been assayed for safety and immunogenicity in seropositive patients. Method: The phase I vaccine clinical trial testing Tat toxoid preparation in Seppic Isa 51 oil adjuvant was performed on 14 HIV-1-infected asymptomatic although biologically immunocompromized individuals (500-200 CD4+ cells/mm3). Results: Following as many as 8 injections, no clinical defects were observed. All patients exhibited an antibody (Ab) response to Tat, and some had cell-mediated immunity (CMI) as evaluated by skin test in vivo and T-cell proliferation in vitro. Conclusion: These results provide initial evidence of safety and potency of Tat toxoid vaccination in HIV-1-infected individuals.

AB - Objectives: To antagonize the deleterious effects of the HIV-1 toxin extracellular Tat on uninfected immune cells, we developed a new strategy of anti-HFV-1 vaccine using an inactivated but immunogenic Tat (Tat toxoid). Tat toxoid has been assayed for safety and immunogenicity in seropositive patients. Method: The phase I vaccine clinical trial testing Tat toxoid preparation in Seppic Isa 51 oil adjuvant was performed on 14 HIV-1-infected asymptomatic although biologically immunocompromized individuals (500-200 CD4+ cells/mm3). Results: Following as many as 8 injections, no clinical defects were observed. All patients exhibited an antibody (Ab) response to Tat, and some had cell-mediated immunity (CMI) as evaluated by skin test in vivo and T-cell proliferation in vitro. Conclusion: These results provide initial evidence of safety and potency of Tat toxoid vaccination in HIV-1-infected individuals.

KW - AIDS

KW - Immunization

KW - Immunotherapy

KW - Tat protein

UR - http://www.scopus.com/inward/record.url?scp=0032057287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032057287&partnerID=8YFLogxK

M3 - Article

C2 - 10195254

AN - SCOPUS:0032057287

VL - 1

SP - 293

EP - 298

JO - Journal of Human Virology

JF - Journal of Human Virology

SN - 1090-9508

IS - 4

ER -

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Cite this